Actively Recruiting
Study Comparing Intravenous Etentamig Plus Daratumumab Versus Daratumumab, Lenalidomide, and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Led by AbbVie · Updated on 2026-10-19
680
Participants Needed
49
Research Sites
43 weeks
Total Duration
AI-Summary
What This Trial Is About
Multiple myeloma is a cancer that affects plasma cells in the blood, often found in bones and bone marrow. It can cause bone pain, fractures, infections, weak bones, and kidney failure. This research aims to study the side effects, disease activity changes, and how the body processes the drug Etentamig in adults with newly diagnosed multiple myeloma who are not eligible for transplant. The study is divided into two phases. In phase 2, participants receive one of three intravenous doses of Etentamig combined with subcutaneous injections of daratumumab, or one of two subcutaneous doses of Etentamig combined with daratumumab. In phase 3, participants receive the recommended phase 3 dose of Etentamig intravenously with daratumumab, or a combination of daratumumab, lenalidomide capsules, and dexamethasone tablets or intravenous injections. The study lasts about 16 years. Participants will attend regular visits at hospitals or clinics for medical exams, blood tests, side effect monitoring, and questionnaires. Researchers will assess adverse events, minimal residual disease, progression-free survival, and quality of life measures over time. The long study duration allows tracking of treatment effects, safety, and disease status across phases 2 and 3.
CONDITIONS
Brief Title
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here